Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857551 | 0.94 | CTSV (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16349674 | 0.88 | — | — | |
| SCHEMBL16349618 | 0.88 | — | — | |
| SCHEMBL16349822 | 0.88 | — | — | |
| SCHEMBL16349582 | 0.87 | CCR2 (0.31) | — | |
| SCHEMBL16349734 | 0.87 | GAA (0.35) | — | |
| SCHEMBL16349581 | 0.87 | GAA (0.35) | — | |
| SCHEMBL16315715 | 0.87 | GAA (0.35) | — | |
| SCHEMBL16349671 | 0.85 | CTSV (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16349686 | 0.85 | CTSV (0.33) | CTSVCTSLCTSBELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | CTSV 33/4885CTSL 109/4885CTSB 199/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | CTSV 1420/4885CTSL 3343/4885CTSB 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.